Genaera Corp

Genaera — Corporate Update (March 2005)

31 slides from Genaera's corporate update, Mar 8, 2005

  1. Slide 1: Teleconference: Corporate Update

    Teleconference: Corporate Update March 3, 2005 © 2005 Genaera Corporation or its affiliates. All rights reserved.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management’s current views and are based on c

  3. Slide 3: Conference Call Agenda

    Conference Call Agenda Introduction Roy Levitt, MD, President and Chief Executive Officer Financial Review John Skolas, JD, MBA, Executive Vice President, Chief Financial Officer and General Counsel AMD Disease Overview Roger Vogel, MD Senior Fellow AMD Program Update Michael Gast, MD, PhD, Executiv

  4. Slide 4: Financial Overview

    Financial Overview (000’s) Cash & Investments, December 31, 2004: $32,151 Results of Operations: Year Ended Quarter Ended December 31, December 31, 2004 2003 2004 2003 Revenues $873 $1,113 $29 $113 R&D Expenses 14,004 7,922 3,612 3,551 G&A Expenses 4,951 2,864 1,403 923 Interest Expense/ (Income) &

  5. Slide 5: Program Highlights

    Program Highlights Four Products in Development EVIZONTM (pronounced ev' -i -zon) Phase II “Wet” AMD development Squalamine Phase II oncology LOMUCINTM/Mucoregulator Phase II cystic fibrosis Alliance with CF Foundation IL9 antibody Licensed to MedImmune, Inc. Phase I

  6. Slide 6: AMD Accomplishments

    EVIZONTM AMD Accomplishments EVIZONTM Accomplishments Trial 207 launch, enrolled, preliminary data presented Trial 208 launched and enrolled Trial 209 launched, enrolling Fast Track Continuous Marketing Application Pilot-2 designee EVIZONTM trade name announced Trial 301 (Phase III International, Pi

  7. Slide 7: Wet AMD Background

    Wet AMD Background Wet Age-Related Macular Degeneration Pathology: neovascularization in the back of eye leads to rapid blindness. Most new products aim to inhibit growth factors influencing abnormal vessels. VEGF and other growth factors are drug targets for these new therapies Current therapies –

  8. Slide 8: Continued Vision Loss With Macugen

    Continued Vision Loss With Macugen® Rapid Early Loss of Visual Acuity – Significant Unmet Need Mean Change in VA (Letters) 0 -2 -4 -6 -8 -10 -12 -14 -16 -18 Macugen® N=291 Sham N=291 12 18 24 30 36 42 48 54 Time (Weeks) Unadjusted, observed Phase III data

  9. Slide 9: Update From The Macula Society Meeting

    Update From The Macula Society Meeting IV Avastin showed significant improvement in VA and in OCT, in both eyes (n=14 patients) – even though several of the eyes had advanced lesions. Bilateral exudative AMD may be seen in one third or more of patients at the time of clinical evaluation. Aggressive

  10. Slide 10: Wet AMD Unmet Needs

    Wet AMD Unmet Needs Current Treatments, Research and Clinical Implications Vision stabilization or improvement is critical Alternatives to avoid chronic frequent intravitreal injections would be welcome Recent data presentations suggests systemic treatments may improve vision in advanced lesions in

  11. Slide 11: EVIZON For AMD: Overview of Characteristics

    EVIZON TM For AMD Overview of Characteristics Potent direct acting anti-angiogenic small molecule which inhibits VEGF and other growth factors Selective uptake by activated endothelial cells with long intracellular half-life and effects Rapid systemic clearance minimizes exposure Excellent safety pr

  12. Slide 12: Summary of AMD Timelines

    Summary of AMD Timelines EVIZON Clinical Plans Trial 207 – (18 patient, open-label PK study) Enrolled – January Report interim results at Macula Society & ARVO Trial 208 – (45 patient, masked, active control (PDT)) Enrolled – February 2005 Interim data anticipated – submitted to ARVO Top line trial

  13. Slide 13: AMD Phase I/II Trial Design

    EVIZONTM AMD Phase I/II Trial 106 Design (40 Treatment Naive Patients, Single Center, Open Label Study) VA Baseline Week 1 Week 2 Week 3 VA Week 4 VA Month 2 VA Month 4 EVIZON Dose, Intravenous (25 or 50 mg/m2) Primary endpoint: safety Secondary endpoints: visual acuity (ETDRS), angiography, fundus

  14. Slide 14: AMD Phase I/II Trial 106 VA Response

    EVIZONTM AMD Phase I/II TRIAL 106—VA Response Seen Early in Treatment Study Eye (Mean Baseline VA 20/125) Visual Acuity in Lines Week 2 Week 4 Month 2 Month 4 (Change From Baseline) (n=40) (n=40) (n=39) (n=39) Positive Change (³ 3 lines) 10 (25%) 13 (33%) 13 (33%) 10 (26%) Stable (£ ± 2 lines) 29 (7

  15. Slide 15: AMD Phase II PK Study Design

    EVIZONTM AMD Phase II PK Study Trial 207 (18 Patients, Multi-Center, Open Label PK Study) PK Screening PK Week 1 PK Week 2 PK Week 3 PK Week 4 PK EOT Month 2 Month 4 EVIZON Dose, Intravenous (10 mg, 20 mg, 40 mg) Primary Endpoints: safety and PK; Secondary Endpoints: visual acuity (ETDRS), OCT, angi

  16. Slide 16: AMD Trial Pharmacokinetic Results

    EVIZONTM AMD Trial Pharmacokinetic Results 40 mg Dose Plasma Profiles Week 1 vs. Week 4 P la s m a S q u a la m in e C o n c (n g /m L ) 6 12 18 24 Time (hrs) (40 mg Infusion Over 40 minutes) Week 1 Week 4 Patient 001-004

  17. Slide 17: AMD Trial Baseline Demographics

    EVIZONTM AMD Trial Baseline Demographics Overall Data – 40mg Group (N=6) Mean Age 80.0 years Male 5 (83%) Female 1 (17%) Angiographic CNV Classification Predominantly Classic 1 (17%) Minimally Classic 2 (33%) Progressive Occult 3 (50%)

  18. Slide 18: EVIZON VA Time Course in Both Affected Eyes

    EVIZONTM AMD Trial EVIZON 40 mg Dose – VA Time Course in Both Affected Eyes Mean Change in VA (Letters) - 2 - 4 - 6 Second Affected Eye N=6 (Mean Baseline 20/320) Study Eye N=6 (Mean Baseline 20/80) EVIZON Treatments Macugen® N=291* Sham N=291* 3 5 8 16 Time (Weeks) * Macugen® Phase III Data

  19. Slide 19: AMD Phase II Trial VA Study Eye

    EVIZONTM AMD Phase II Trial 207 VA – 40 mg vs. 10 mg Dose—Study Eye Visual Acuity Score (ETDRS) Letters Week 3 ** EOT *** Month 2 Month 4 (Change From Baseline*) N=6 N=6 N=6 N=6 40 mg Mean Letters Change + 6.8 + 8.2 + 2.7 0 Range Letters Change +18 to - -5 +18 to 0 +14 to -9 +18 to -12 Visual Acuity

  20. Slide 20: AMD Trial Preliminary Safety Information

    EVIZONTM AMD Trial Preliminary Safety Information No drug-related serious adverse events (SAE) Some injection site pain No drug-related ocular AEs No cardiovascular AEs

  21. Slide 21: EVIZON Clinical Conclusions

    EVIZONTM AMD Trial EVIZONTM Clinical Conclusions Minimal systemic exposure (terminal T1/2 ~7 hours) is associated with excellent safety profile to date Vision stabilization or improvement is observed as early as Week 3 Systemic 40 mg dose of EVIZON preserves or improves vision in all patients throug

  22. Slide 22: Competitive Advantages Summary

    EVIZONTM Competitive Advantages Summary Improvement or preservation of vision possible Potential to treat both affected eyes – about 1/3 to 1/2 of patients have both eyes affected simultaneously Synergy with other therapies possible Intravenous EVIZON delivery avoids the complications associated wit

  23. Slide 23: Phase III Update

    EVIZONTM Phase III Update EVIZONTM Clinical Plans Trial 209 (runs concurrently with Phase III, used for final sample size estimates during Phase III) Special Protocol Assessment Submitted Trial 301 (Phase III International, Pivotal Registration) Anticipate Initiation Q2 ‘05 Trial 302 (Phase III Inte

  24. Slide 24: EVIZON Wet AMD Market

    EVIZON TM WET AMD MARKET Favorable Environment Competitive Landscape Business Development/Partnering

  25. Slide 25: Wet AMD Market: Favorable Environment

    EVIZON TM WET AMD MARKET Favorable Environment Huge unmet medical need Incidence/Prevalence numbers large & growing 30-50% have disease in both eyes Pricing continues to be favorable Pharma’s need for Phase III drugs still there

  26. Slide 26: Answering the Unmet Medical Need

    EVIZON TM WET AMD MARKET Answering the Unmet Medical Need Improvement or preservation of vision possible Potential to treat both affected eyes 30 to 50% of patients have both eyes affected Intravenous EVIZON delivery avoids the complications/side effects associated with intravitreal injections No ea

  27. Slide 27: Wet AMD Market: Competitive Landscape

    EVIZON TM WET AMD MARKET Competitive Landscape Macugen approved Alcon slowed Competitive products have not addressed the unmet medical need Rapid market growth (More patients, longer treatments, better drugs, combinations) Total market may exceed $5 Billion in next few years Reimbursement pathway be

  28. Slide 28: Partnering: Where Are We Today?

    EVIZON TM WET AMD MARKET Partnering WHERE ARE WE TODAY? Gaining valuable knowledge & experience Moving to Phase III Market Research Positive response from retinologists and ophthalmologists IV Administration advantage over intravitreal administration Safety/side effect profile is significant advanta

  29. Slide 29: Partnering (This is not guidance!)

    EVIZON TM WET AMD MARKET Partnering (This is not guidance!) See our negotiating position continuing to improve (data) Competitive landscape improving Market is increasing Data is good to date Keep the program moving rapidly Multi-Billion dollar sales potential

  30. Slide 30: Partnering

    EVIZON TM WET AMD MARKET Partnering Genaera and stockholders have taken all the risk to date Phase III partnership deals have best economics Entering Phase III in 1H 2005 Macugen & Lucentis both in Phase III when partnered Term sheets have been received Not there yet Do want good economics, willing

  31. Slide 31: Anticipated Milestones

    Anticipated Milestones EVIZONTM Trial 207 AMD—interim data H1 2005 Trial 208 AMD—interim data Q2 2005 Trial 208 AMD—primary data Q4 2005 Trial 209 AMD—enrollment complete Q1 2005 Trial 301 AMD—start H1 LOMUCIN™/Mucoregulator Update on Phase II plans Q1 2005 Patents As issued IL9 antibody Phase I dat

Genaera — Corporate Update (March 2005) on 6ix